ClinicalTrials.Veeva

Menu

Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma

Stanford University logo

Stanford University

Status

Completed

Conditions

Metastatic Renal Cell Cancer

Treatments

Device: perfusion computed tomography

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT01926990
RENAL0026
NCI-2013-01626 (Registry Identifier)

Details and patient eligibility

About

This pilot clinical trial studies perfusion computed tomography (CT) in predicting response to treatment in patients with advanced kidney cancer. Comparing results of diagnostic procedures done before, during, and after targeted therapy may help doctors predict a patient's response to treatment and help plan the best treatment.

Enrollment

19 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Suspected or biopsy-proven renal cell carcinoma
  • Treatment planned with sunitinib, pazopanib, sorafenib, bevacizumab, axitinib, nivolumab alone or in combination with an investigational agent
  • Ability to understand and willingness to sign a written informed consent document

Exclusion criteria

  • Serum creatinine greater than or equal to 1.7 mg/dL
  • Severe allergy to contrast agent
  • Any contraindication for undergoing a CT scan
  • Pregnancy or unwillingness to use preventative measures if a woman of child-bearing potential

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems